Dear Colleagues,

Translation is the process of turning observations in the laboratory, clinic and community into interventions that improve the health of individuals and the public, and observations in the community, public, and clinic into the laboratory. In Breast Cancer patients, at the end of the 19th century, ‘translational scientists’ turned the observation that some breast cancers regressed after menopause into the first effective hormone treatment (oophorectomy) for breast cancer and subsequent pharmacologic interventions along the hormone axis, such as estrogen receptor modulators and antagonists and aromatase inhibitors. At the end of the 20th century, new techniques for observation led to the discovery that the HER2 protein identified a particularly aggressive type of breast cancer, and led to the therapeutic development of Trastuzumab and subsequent HER2-targeted therapies, including small molecules, additional antibodies, and anti-body drug conjugates.

Observations leading to hypotheses, leading to understanding, leading to improved outcomes have been the heart of medicine from the late 1800s and continue today. This Special Issue will highlight some translational aspects of research on the treatment of patients with breast cancer today.

Dr. Andrew G. Robinson
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• breast cancer
• translational research
• treatment
• patients
• outcomes